Thanks Gator Man. Yes, I agree, additional information from the Cosmos trials has to be good news for anyone hoping to get approval for Sovaldi/Olysio `off label` treatment in future.
It`s also been announced that phase 3 trials have been initiated to evaluate this drug combo, which is an important step forward.
I was reading about this earlier and I`ve posted more details in the HCV News section...
I was told that there will be new data presented regarding the COSMOS trial at the upcoming EASL-ILC meeting in London. While I am not privy to any specifics, I was informed that the results will be favorable in general, and especially for cohort 2 consisting of treatment naive and prior null responders who are Metavir F3-F4. I assume that they will have the percentage who reached SVR12, with and without Ribavirin, from this (my own) group.
For those of us with advanced liver disease who can't wait for the next generation of DAAs, these results may be important to support commencing treatment immediately with a significant chance of achieving SVR. It hopefully will add some ammunition when dealing with insurance companies regarding treatment costs. Time will tell.
Thanks Gator Man. Yes, I agree, additional information from the Cosmos trials has to be good news for anyone hoping to get approval for Sovaldi/Olysio `off label` treatment in future.
It`s also been announced that phase 3 trials have been initiated to evaluate this drug combo, which is an important step forward.
I was reading about this earlier and I`ve posted more details in the HCV News section...
http://hepcfriends.activeboard.com/t57209465/phase-3-trials-evaluating-simeprevir-and-sofosbuvir-have-bee/?page=1#lastPostAnchor
I was told that there will be new data presented regarding the COSMOS trial at the upcoming EASL-ILC meeting in London. While I am not privy to any specifics, I was informed that the results will be favorable in general, and especially for cohort 2 consisting of treatment naive and prior null responders who are Metavir F3-F4. I assume that they will have the percentage who reached SVR12, with and without Ribavirin, from this (my own) group.
For those of us with advanced liver disease who can't wait for the next generation of DAAs, these results may be important to support commencing treatment immediately with a significant chance of achieving SVR. It hopefully will add some ammunition when dealing with insurance companies regarding treatment costs. Time will tell.